- Poster presentation
- Open Access
How do clinical researchers’ and patients’ preferences influence study hypotheses and reported outcome results for clinical randomised controlled trials? A critical appraisal
© Rosati et al; licensee BioMed Central Ltd. 2015
- Published: 29 May 2015
- Randomise Control Trial
- Discrepancy Score
- Clinical Trial Registry
- Outcome Result
- Grade Method
Studies designed to promote unbiased research increasingly show that human preferences exert a major influence on randomised controlled trials (RCTs) [1–3]. More information is needed on how preferences influence clinical trial design and conduction [4–6]. To fill the information gap between what researchers seek and report and what patients want [7, 8], in this study we investigated how researchers’ and patients’ preferences influence study hypotheses and outcome results of published clinical RCTs. Because conventional critical appraisal seemed inappropriate for addressing our research question, in this pilot study we developed a novel assessment method and applied it in an RCT sample.
We collected 20 unselected and consecutive RCTs published in a high impact paediatric journal from July to November 2013. Two experienced reviewers identified the following five domains and a grading method to score discrepancy between what author’s state in clinical trial registries (CTRs) and report in published RCTs: reported funding (1 point), study hypotheses, information on patients enrolled and study conduction (3 points); primary and secondary outcomes, early study completion, and upgrading or downgrading outcome results (5 points). Higher scores implied marked discrepancy. Two reviewers then independently applied the method on the RCT sample by mapping and coding information for the domains identified and reported discrepancies by comparing CTRs and RCTs (Table S1, Additional file 1).
Of the 20 RCTs collected and CTRs compared, 14 studies had high total preference discrepancy scores (7 scored 10-12, and 7 scored 16 or more) and 4 had discrepancy in declaring funding. In 12 studies researchers completed the study early and in 8 studies they downgraded or upgraded outcomes. Only 5 CTRs were updated but they neglected to include published RCT results. Only in 5 CTRs, dataset supervisors indicated the RCT URL. None of the 20 RCTs allowed us to assess patients’ preferences (no information reported for non-response and refusal). No difference was found in discrepancy scores among the five CTR databases.
The high discrepancy scores obtained by comparing what researchers stated in CTRs and published in RCTs suggest possible misconduct. Patients’ preferences during RCT enrolment and conduction remain undetectable owing to the lack of targeted protocols to elicit this issue. These results, if confirmed in further studies, should prompt international regulation developers  to encourage researchers to explore patients’ preferences as a strategy to enhance informed decision-making and to improve reporting in RCTs and CTRs.
- King M, Nazareth I, Lampe F, Bower P, Chandler M, Morou M, et al: Impact of participant and physician intervention preferences on randomized trials: a systematic review. JAMA. 2005, 293: 1089-99. 10.1001/jama.293.9.1089.View ArticlePubMedGoogle Scholar
- WHO Statement on public disclosure of clinical trial results. Call for public consultation. 2014, [http://www.who.int/ictrp/results/en/]
- Walker E, Nowacki AS: Understanding equivalence and noninferiority testing. J Gen Intern Med. 2011, 26: 192-196. 10.1007/s11606-010-1513-8.View ArticlePubMedGoogle Scholar
- Stengel D, Sehouli J, Porzsolt F: Are the results of randomized trials influenced by preference effects? Part I. Findings from a systematic review. Optimizing Health-Improving the Value of Healthcare Delivery. Edited by: Porzsolt F, Kaplan RM. 2006, New York: Springer, 265-291.View ArticleGoogle Scholar
- Porzsolt F, Stengel D: Are the results of randomized trials influenced by preference effects? Part II. Why current studies often fail to answer this question. Optimizing Health- Improving the Value of Healthcare Delivery. Edited by: Porzsolt F, Kaplan RM. 2006, New York: Springer, 292-297.View ArticleGoogle Scholar
- Ioannidis JPA, Greenland S, Hlatky MA, Khoury MJ, Macleod MR, Moher D, et al: Increasing value and reducing waste in research design, conduct and analysis. Lancet. 2014, 383: 166-75. 10.1016/S0140-6736(13)62227-8.View ArticlePubMedPubMed CentralGoogle Scholar
- Wade J, Donovan JL, Lane JA, Neal DE, Hamdy FC: It’s not just what you say, it’s also how you say it: opening the ‘black box’ of informed consent appointments in randomised controlled trials. Soc Sci Med. 2009, 68: 2018-2028. 10.1016/j.socscimed.2009.02.023.View ArticlePubMedGoogle Scholar
- Mills N, Donovan JL, Wade J, Hamdy FC, Neal DE, Lane JA: Exploring treatment preferences facilitated recruitment to randomized controlled trials. J Clin Epidemiol. 2011, 64: 1127-1136. 10.1016/j.jclinepi.2010.12.017.View ArticlePubMedPubMed CentralGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.